Adoptive immuno-gene therapy of cancer with single chain antibody [scFv(Ig)] gene modified T lymphocytes.
J Biol Regul Homeost Agents
; 18(2): 134-40, 2004.
Article
en En
| MEDLINE
| ID: mdl-15471217
Adoptive transfer of antigen-specific T cells has recently shown therapeutic successes in the treatment of viral infections and tumors. T cells specific for the antigen of interest can be generated in vitro, and adoptively transferred back to provide patients with large numbers of immune-competent T cells. Adoptive T cell therapy, however, is a patient-tailored treatment that unfortunately is not universally applicable to treat viral infections and tumors. We and others have demonstrated that the transfer of genes encoding antigen-specific receptors into T cells (i.e., genetic retargeting) represents an attractive alternative to induce antigen-specific immunity. Currently, we evaluate this concept in a clinical protocol to treat patients with metastatic renal cell cancer (RCC) using autologous RCC-specific gene-modified T lymphocytes.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Fragmentos de Inmunoglobulinas
/
Carcinoma de Células Renales
/
Linfocitos T Citotóxicos
/
Inmunoterapia Adoptiva
Tipo de estudio:
Guideline
Límite:
Animals
/
Humans
Idioma:
En
Revista:
J Biol Regul Homeost Agents
Asunto de la revista:
BIOLOGIA
/
BIOQUIMICA
Año:
2004
Tipo del documento:
Article
País de afiliación:
Países Bajos
Pais de publicación:
Italia